☆ 4.5 Letter

Reply to Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study

Alice Canzian et al.

Summary: The study suggests that RTX may be effective in treating relapses of EGPA vasculitis. MEPO is highly effective with a good safety profile in patients with GC-dependent asthma.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Letter Allergy

Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase

Marco Caminati et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Review Allergy

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine

Ian D. Pavord et al.

Summary: The development of mepolizumab, an anti-IL-5 monoclonal antibody, for the treatment of severe eosinophilic asthma exemplifies how clinical programs can evolve over time based on scientific principles. Initially disappointing results led to a shift in focus towards more severe patients, leading to clinically meaningful benefits in a targeted population identified through biomarker research. This personalized approach ultimately resulted in new and effective treatments for severe asthma.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Letter Allergy

Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?

Florie Akdime et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Article Medicine, General & Internal

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

M. E. Wechsler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Immunology

Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Vincent Cottin et al.

AUTOIMMUNITY REVIEWS (2017)

添加到收藏夹

Reply to Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?

相关参考文献

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study

Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine

Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

导出引文

分享论文